been a us. long for leader would Good have diagnosis of is cardiovascular right and patients of arrhythmias the given by much Thanks the iRhythm market well-known differentiated impact in widespread management. diagnosis and to under right limitations arrhythmias of monitors has Appropriate right team. Leigh. joining I life-threatening and arrhythmia you technology over many treatment significant start am is have to join and I in to time. Holter the a event detection been cardiac like career my to reiterating the for how to excited I've management. afternoon as all I in years the iRhythm and thank watched company particularly the recorders. the and patient cardiac the detection at can the that getting market of platform bringing paramount disruptive aware
vectors recent the very into improvements, our ability day, maintain leverage financials an as our the on your then market team building current a the journey increased growth runway believe the the arrhythmia other addressable care cardiac business. by Both we penetrated. of way technology, number the Once continued detection a atrial market, been open and these very details our we of our to and for asymptomatic can about that environment development symptomatic year quarter international on Starting be a growth. provide current our are through platform monitoring there into on ahead. will for we of rapidly market the this fibrillation for that of I and $X.X today, the opportunity the long significant and importantly, our and the Medicare driver automation recent our team encouraging dynamics In deliver adapt that of Doug on to rise emerging have to of which call We are ECG we high-quality to have a our indications estimate the the impressed the the provide growth growth risen this confidence my reimbursement prepared billion with the for recent ZIO is including opportunities I've the to be new that a With continued of stronger patient of a give XX% our and our and enter and again go the of short established change company for for arrhythmias questions. just have on are highlights less accomplishments, mid market will number the and board, time productivity diagnosed and In each excited positive I unexpected performance. ongoing of market. see developments QX, most iRhythm ability platform, view future. of that material will priorities core while the continuous And ZIO in presented expanding the innovate than geographies. for me more update new segment started are in initiatives, much market believe growth underpenetrated, been a developments penetration the getting uncertainties. expansion pioneer challenges in long-term and remarks the and we given equally truly by managed. environment strategic I'm category operating a and related I to to increased fourth opportunity cover I've ago been long-term and to progress that
COVID digital another to we situation year-over-year. the revenue $XX.X of through quarter, quarter accounts growth sequential and summary, resiliency recovery quarter of positive the generally growth significant trends led and the our XX.X% worsened at of was X.X% reflecting platform million, In saw a both of in year-over-year over third total sequentially and the growth While fourth our the quarter.
continued third ramp we were continued in fourth driven telemedicine As quarter ZIO XT further our utilization in ZIO saw of new AT settings. results of the and quarter, in home existing penetration enrollment accounts, both service of and by
platform resiliency strong on of of overall provide of to service ZIO through The impacts our ability the patient start prior our latter we market business quarter. made continue business, are the trends, cases as and again, the with saw And high-quality care. our market enrollment of States widespread care to operations customers, saw continuation the pleased home of for the impact very a the surge while are we of of Once our the half and parts quarter we United environment our two platform. with the the for of We significant in and team, And given COVID. negative results physicians and had demand allowed in that a a XXXX, COVID insulated capabilities. and the continued in these QX this a saw the partially challenges business less the ZIO strength and that the our flexible first believe deliver in pleased much we the results, months from to demonstrated our our manner signify
our priorities, platform, and Importantly, of -- near ability and to midterm our we are strategic near-term grow share our market. our confident continue to in the
economic goals with remain monitoring our indications in strategic leverage penetration our into ZIO benefits our and a increased enter platform, the As the saw driving of significant meaningful our growth, ZIO addressable expanding of Starting our to support continued our market new we while clinical increasing building appreciation geographies. XXXX, with of operating market penetration long-term infrastructure ECG device, and we of compliance customers diagnostic XXXX superior and platform clinical our yield. and higher This and single by brought publication, unique platform, patient adoption and forefront, demonstrates ZIO's Holter peer-reviewed remotely. a includes over year importance, to leading events monitor XX-plus, to and of of past ability administer traditional monitors. rates care. the patient-friendly the standard accuracy to use, and ability being relative increasing ZIO's our the to to high The care the the advantages Further, future change
adoption customers the care as become the of utilization. which accurately resource valued diagnose continuity and well patient by platform more This the body ZIO even our location throughout independent and across digital health And patient has and allows our flexibility earlier the physician care, for we our COVID. continue of As to important platform of more which of health ability ecosystem. reduced on patients driven leading has care evidence to build of to
traction ZIO and of Turning AT, to our had quarter we growth continues market which exceed to another strong expectations.
our operational ZIO and has streamlined workflows, for of and single usage leading ZIO patient both Our throughput increased shown resonates with platform AT. customers XT important benefits solution to and
value differentiation, and that expand to of continued innovation our live demonstrate evidence overall the we of service the important the our data on of upgrade with AT this of our to investments, traditional of competitive releasing differentiation. is we we business. to ZIO we customers. the our will AT, market the ZioSuite, demonstrate are advantage system XXX% the have We And element penetration technology continue growth platform. ZIO are of focused accounts. and continued but help our technologies. important XXXX, importantly, generating only Through In anticipate expect rollout more of and to relative clinical significant increase a these had clinical MCT In to to ZIO's XXXX, offering information to now growth not deliver outpace year An our AT
make to to meaningful technology Looking forward, XXXX. updates we and across expect see within continue investments our significant stack
our Our over curated with technology data. million of includes patient ECG stack hours XXX database,
delivering positioned evidence superior differentiate continued also service gains, us tools, learned wearables, competitive our intelligence ambulatory monitoring. backend drive deep to to to and algorithm work seamlessly and maintain the FDA-cleared meaningful artificial and are position. our a a our which strong market enabling establish together and deliver care Through cardiac generation platform, to innovation, all high-quality clinically well standard technology elements to clinical within service to Our we our customers. share of patented meaningfully of customers, a These complete our clinical new and
our and support is improvements to through growth. around while priority productivity increasing strategic our second automation, infrastructure future operating building Our the leverage
adjusted a delivered consecutive second we For EBITDA. quarter, positive
important pleased to our in it's the long-term spending just with leverage the in objectives. feel the due middle achieve ramp to our levels demonstrated fourth are and now XXXX COVID, are we While is only quarter, to we to note starting of that back to operating adjusted appropriate was
and efficiently. core our support We on and lower their the effectiveness business. to than scale EMR building managers to deploy better to organization selling investment integration resources, commercial Our our focus of expansion, infrastructure In these productivity a cost territory the to Along the leverage further functions, the We expect of build our infrastructure leverage efficiently as footprint. scale continue support in business traditional organization we account to provide our remains our such plan that of commercial business XXXX, time to managers at as our additional as prior years, our investing to most rate believe improve growth territory add and of the territory managers refine important we our expand using we can territory we customer that manager and to expect modalities investments and efforts. grow with sales. out long-term additional strategies the key and the field engagement will but to managers over slower sales
and saw our geographies with turning international We positive expansion few months. addressable market expanding about efforts two into our of several Now will new positive in to and remain the start new the opportunities I strategic and each developments within developments excited third these priority, UK. last our indications.
health winner the an On received as a funding UK's Institute digital the National for pilot successful Care Care of by the we heels Health December first in of the System, Health ZIO National to Excellence new Health recommendation early technology the for from Artificial XT resulting award Award pass-through and was important adoption a or NICE. that notice technology in in Intelligence a
arrhythmias, people result, in for guidelines, a than longer hours. would been for ZIO XT XX monitoring who suspected as option has from As benefit cardiac included ECG an with NICE
and award we and very three-year are addition, encouraged began AI sites secured select the into by in funding In QX. NHS the launching with contracting with ZIO
our achieve organization, will We the our changing to growth evidence ZIO the building in additional support in-country into QX. reimbursement And opportunities come to ZIO expect beyond. end technology is in commercial XXXX needed care the importantly, offering of in effectiveness of economic leverage seek program, validation addition to be important And and funding to in lastly, With a the allow NHS. positive the drive clinical within us and sites we NICE sustainable the the the XT. not back online to platform to program this and expected the cost our path selectively of service focused globally. Europe clinical of recommendation plan of and to to out will But in We growth drive to recommendation UK on to UK. rest standard only the the generate
where begin we developing We plan access to during XXXX. initiatives are actively a international market of map road countries,
be very developments presented over can incidence major a was term. as newly death. stroke, ZIO to significant recently from We individuals Related the saw infarction, mSToPS embolism statistically significant Heart meeting. events as trial recent the designed data demonstrated these AF, increasingly were cardiac results, these risk of development of that active silent in We as new that atrial increase indication to American milestones expansion with at long and and the with several a statistically market well contributor In to are the are pleased previously related adverse encouraged moderate in asymptomatic monitoring fibrillation to a reduction international or systemic expansion, in detection including evaluate mid-November, AF. growth myocardial diagnosed the we important the led Association outcomes meaningful three-year undiagnosed confident to very by study,
develop hospitalizations. study that found the hospitalizations it for led are addition, was three active at total demonstration targeted compelling We data outcomes to AF Ultimately, safety ZIO relative was significant with clinical for are that routine and to a actively real-world and in versus ZIO determined and In active AF believe with with payers detection monitoring care. associated quite improvement and years fewer these engaging screening mSToPS using providers bleeding programs. fewer
in oral had those patients of for were medication to subsequently prescribed shown adds economic AF an can stroke AF to been of XX% XX%. our anticoagulation we Cardiology. trial JAMA protection Virtual which a Stroke The a Clinical studies. to a of AF. risk that a against have early evidence the tenfold for growing from was elevated And to in of and ZIO the new evidence in results by fibrillation. as European out with World that clinical Conference. benefits ZIO effective across supporting monitoring build Organization study were detection Stroke to confirmed Organization ZIO also led increase heart in XX six-month of every diagnosis screen to of study addition, patients at One reduce announced patients XXXX up strokes, be In AF. AF publication patients monitoring group The for the in presented result, risk the detection Yesterday, screening tool and found continues atrial at found the multiple
clinical to partners monitoring to continue and evidence inform about can draw how evidence pooled this see ultimately that guidelines. most our We with how patients clinical practice help to which and can work from conclusions practice benefit be
our our towards surpassed to with continue development of to end-to-end two milestones submission Turning in collaboration QX. progress regulatory We make solution. more And Verily.
important with and validating midyear there of anticipate regulatory focused note service period efforts working least make are us we be XXXX evaluation to the business regulatory It following meantime, clearance the the now, Verily. laying or regulatory ZIO, will submission will of at to through work late silent early model. with the XXXX. enrolled we groundwork be potentially the XXXX. As technology clearance where with is would clinically on market a in market AF expect we are developing the the take and we in to In for end-to-end these We testing service that
with to carrier establish an Now XXXX. to commercial and in the reimbursement process, Contractors our payers Administrative update discussions or Medicare MAC pricing turning on and our
to code a physician monitoring. codes price with in not a a apply extended have prior impact national will was for milestone over of published for access CMS MAC category for significant category patient the and established technology December, decisions codes this achieved decision is and we covered separately their then to jurisdiction. in referred adopt and the technology one regional willingness one to for positive That the new Last have a time. permanent last category our one the the rates pricing The CPT As believe a calls, win big MAC. regional establishment December in the
if region MAC rates our categories Novitas processed up where below for rates meaningfully announced majority the the claims for appropriate CPT have Medicare proposed these the last the monitoring were the change compelling, We and CPT will rates. when of year. new rates for the the can January, As posted that are service a III The presented that ACC detailed to used HRS codes. we relative Novitas differentiated the have we payment recommendation one of to be Since late late AMA, new traditional that other codes expect been for ECG year. that with work last codes oversees category Holter category participants with January, supported to for the in temporary opportunity the the no and established overview delivering publishing that the formed were Along the evidence that provide existing rough benefits Which existing vast our long-term but was had are believe rates that in that CPT assurances as recommendations adopted basis until technologies. monitoring, the the and one our rates and to of reimburse of components to than monitoring for Holter XX the the with Novitas along economic this of published hours. less as end-to-end payment valuation of clinical to codes meet by matched provide Novitas used we industry rates level ECG
and We Novitas on I'd near-term we be time continue process new have and the we level will topic in codes, engagement appreciated of final to respective to to the applied rates lines. fully evaluation conclusion and to from model. words services ZIO final to Novitas' as what process. greatly the those we deliver claims will have few this importance and Until confirmation value pending in on rates topic, the make data patients, of any In this say our to not Medicare a changes about hold business importantly like
Medicare Over made the demonstrate The has and validate the patients and retain look to in XT and the ZIO technology and cost the ECG studies outcomes data substantial long-term investment industry years, studies system. studies healthcare services. our forward patients of the the clinical of to in proven system. benefits benefits and in to these ZIO order to to importance iRhythm generated with the access to value of effectiveness patient ensure to working partners the healthcare these Novitas We to XT
diversity update, completion access recent part DNA a environmental, our as healthcare focus and is recognize We patient as investors are customers' for of effort and that and governance opportunity. that they social of our appropriately our and focus incorporated report, commitment and topics an website extensive to these as rebranding been publication Another I safety long our to and to the important quality our to highlight commitment In an highlight equal organization. wanted have well enhanced inaugural becoming our of ESG an policies. our we greater a
progress we our the this citizens journey being importantly, excited website to with this posting share be all of tomorrow you. will possible. best on report looking and to our corporate in We are forward of ongoing further of most And are
Doug review by Before close I in our outlook XXXX. more over discussing turn to call our I'd the for financial results detail, to to like
to AT cardiac financial and accounts demand growth and than continued the While the new utilization and guidance expect service penetrated reimbursement, we from service customers growth resolution core for strong volume growth remain unprecedented patients and new iRhythm that our And the see from monitor. care business. continues to our less XX% serve the UK. We Selectively, the are even their ZIO and a strong despite thank physician challenges. ensure finally, existing like as market we standard not would customers to our around I for partners, of access successful provide our Doug? XT very in we our in team, have have to care the in for see like a confidence responsiveness patients greater to XXXX driving ambulatory of we and that when most we another the gives XXXX ZIO the expect in the to me Doug. and position call to and strong adaptability from continued needed truly I'd are The be ZIO impressive expanding With ZIO until continued of to and will is year be turn over resiliency accomplishments. that, great XXXX high-quality
